Purple Biotech Ltd. (PPBT)
NASDAQ: PPBT
· Real-Time Price · USD
2.34
-0.01 (-0.43%)
At close: May 02, 2025, 3:43 PM
2.35
0.43%
After-hours: May 02, 2025, 05:51 PM EDT
-0.43% (1D)
| Bid | 2.35 |
| Market Cap | 33.32K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.24M |
| EPS (ttm) | -49.9 |
| PE Ratio (ttm) | -0.05 |
| Forward PE | -1.49 |
| Analyst | Buy |
| Ask | 2.36 |
| Volume | 76,997 |
| Avg. Volume (20D) | 98,106 |
| Open | 2.32 |
| Previous Close | 2.35 |
| Day's Range | 2.25 - 2.44 |
| 52-Week Range | 2.00 - 20.60 |
| Beta | -0.11 |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2015
Employees 9
Stock Exchange NASDAQ
Ticker Symbol PPBT
Website https://purple-biotech.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PPBT stock is "Buy." The 12-month stock price forecast is $33, which is an increase of 1310.26% from the latest price.
Stock Forecasts3 days ago
-5.14%
PPBT stock has given up its prior gain. Purple Bio...
Unlock content with
Pro Subscription
3 days ago
-5.14%
Purple Biotech shares are trading higher after the company's CM24 showed up to a 90% reduction in the death risk for pancreatic cancer patients and announced it will commence a Phase 2b study.
